Collagen News and Research

Latest Collagen News and Research

New cell regeneration method uses gene therapy to repair bone tissue

Researchers at the Royal College of Surgeons in Ireland (RCSI) have developed a new method of repairing bone using synthetic bone graft substitute material, which combined with gene therapy, can mimic real bone tissue and has potential to regenerate bone in patients who have lost large areas of bone from either disease or trauma.

25 Jul 2012

Questcor second quarter net sales increase to $112.5 million

Questcor Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2012.

24 Jul 2012

Ellman International acquires Sandstone Medical Technologies

Ellman International, Inc., a global leader in advanced radiofrequency (RF) technology for precision surgical and aesthetic procedures today announced that it has acquired the assets of Sandstone Medical Technologies, LLC., a recognized leader in the aesthetic laser and IPL technology field.

19 Jul 2012

Nanofiber scaffolds regenerate protein components in cartilage repair

Johns Hopkins tissue engineers have used tiny, artificial fiber scaffolds thousands of times smaller than a human hair to help coax stem cells into developing into cartilage, the shock-absorbing lining of elbows and knees that often wears thin from injury or age. Reporting online June 4 in the Proceedings of the National Academy of Sciences, investigators produce an important component of cartilage in both laboratory and animal models.

18 Jul 2012

Jade, BioTime sign exclusive sublicense and supply agreement for HyStem

BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement and a supply agreement with Jade Therapeutics, LLC, a developer of an ophthalmological therapeutic sustained-release drug delivery platform.

18 Jul 2012

InvivoSciences, WUSTL to construct artificial tissue models for heart failure

The National Institutes of Health has awarded more than $2 million to a team of scientists from Washington University in St. Louis and InvivoSciences, a biotechnology startup with WUSTL roots, to construct artificial tissue models that will allow the rapid testing of new drugs for heart failure.

17 Jul 2012

Mechanical treatment shows promise in thalassemia

Vibration therapy may be an effective nonpharmacologic intervention to increase bone mass in patients with thalassemia, US researchers report

10 Jul 2012

Special surface coating for stents to keep them in place

If a person's windpipe is constricted, an operation in which the surgeon inserts a stent to enlarge the trachea is often the only way to relieve their respiratory distress. But this grid-like implant can slip out of position, closing off the windpipe altogether. Researchers are working on a special surface coating for the stents to keep them in place.

9 Jul 2012

Cystic fibrosis patient receives generous 'gift of life'

Meara Schmidt, 28, almost died a few weeks ago. Lying in her hospital bed at UCLA, the seriously ill cystic fibrosis patient felt herself slipping away and her life flashing by. But then the image of her husband appeared, and she knew she was not ready to go.

7 Jul 2012

FDC precursor cells exist in the wall of blood vessels

Chronic inflammatory conditions are extremely common diseases in humans and in the entire animal kingdom. Both in autoimmune diseases and pathogen-caused diseases, the inflamed areas are rapidly colonized by antibody producing B lymphocytes - which organize themselves in highly structured areas called "lymphoid follicles".

6 Jul 2012

Data from Infinity’s IPI-145 pre-clinical study on inflammatory diseases

Infinity Pharmaceuticals, Inc. today reported preclinical data for IPI-145, the company's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The data demonstrate potent PI3K-delta and -gamma inhibition in biochemical, cellular and whole blood assays and activity in multiple preclinical models of inflammatory disease, including rheumatoid arthritis and asthma.

28 Jun 2012

MAQUET's INTERGARD SYNERGY vascular graft receives CE mark

MAQUET Cardiovascular, LLC announced today that it has received CE mark for its INTERGARD SYNERGY vascular graft. This graft represents the next generation in antimicrobial grafts combining the well-known antimicrobial properties of silver acetate and triclosan.

19 Jun 2012

Health Canada approves Viveve System to improve sexual function after childbirth

Viveve, Inc., a woman's health company and pioneer in non-surgical vaginal tissue restoration, announces Health Canada has issued a Medical Device License for the Viveve System to treat laxity of the vaginal introitus (opening) after vaginal childbirth, to improve sexual function. The Viveve procedure is the first of its kind and clinical results have shown an improvement in the feeling of vaginal tightness and sexual satisfaction for women.

18 Jun 2012

Biomarkers predict progressive spinal damage in ankylosing spondylitis

German researchers have discovered five biomarkers that may predict the progression of structural damage in the spine of patients with ankylosing spondylitis who are already at high risk for disease progression.

8 Jun 2012

What are vitamins?

Most people have heard of vitamin C and its effects upon the body; but how much do you know about other vitamins? How many even are there? And what do they all do?

8 Jun 2012

Positive updated interim data from Exelixis’ cabozantinib phase 2 trial on CRPC

Exelixis, Inc. today reported positive updated interim data from an ongoing phase 2 trial of cabozantinib in men with metastatic castration-resistant prostate cancer (CRPC) and bone metastases.

6 Jun 2012

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced results from a study of ABRAXANE(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer.

5 Jun 2012

Positive results from BioSpecifics’ XIAFLEX Phase III clinical program on Peyronie's disease

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe and Eurasia, today announced positive top-line results from the IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) Phase III clinical program of XIAFLEX for the treatment of Peyronie's disease, which was conducted by BioSpecifics' partner Auxilium Pharmaceuticals, Inc.

5 Jun 2012

Positive results from Auxilium’s XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

4 Jun 2012

MD Bioproducts launches new subtype specific antibody as marker for AS

MD Bioproducts launches a new subtype specific antibody as a marker for ankylosing spondylitis (AS): HLA-B*2705. The anti-HLA-B*2705 antibody, clone MARB4, has been validated for use in flow cytometry, tissue staining and immunoprecipitation.

30 May 2012